Small glutamine-rich tetratricopeptide repeat co-chaperone alpha (SGTA)

Small glutamine-rich tetratricopeptide repeat co-chaperone alpha (SGTA) is a ubiquitously expressed, cytoplasmic protein characterized by a central tandem array of three tetratricopeptide repeat (TPR) motifs and a glutamine-rich C-terminal domain. SGTA acts primarily as a molecular co-chaperone, regulating the folding, trafficking, and activity of client proteins, especially steroid receptors (such as androgen and growth hormone receptors) and viral proteins. It functions in multiprotein complexes to modulate hormone signaling, cell cycle progression, apoptosis, and protein quality control, including targeting misfolded proteins for endoplasmic reticulum-associated degradation or proteasomal sorting. SGTA is implicated in several pathological processes—prostate and ovarian cancers, polycystic ovary syndrome, neurodegenerative diseases, and viral infections—and interacts with chaperone proteins (HSP70, HSP90), membrane insertion machinery, and viral components. Although no drugs directly target SGTA to date, its central role in regulating hormonally-driven cell processes and maintaining protein homeostasis makes it a potential therapeutic target and biomarker for related disorders.

Other names

Small glutamine-rich tetratricopeptide repeat-containing protein alphaSmall glutamine-rich tetratricopeptide repeat (TPR)-containing, alphaSmall glutamine rich tetratricopeptide repeat containing alphaProtein containing three tetratricopeptide repeatsViral protein U-binding proteinVpu-binding proteinAlpha-SGTSGT1SGThSGTUBP

Would be expected to modulate SGTA’s co-chaperone activity, alter hormone receptor folding/localization, or interfere with its role in viral protein processing. Inhibitors may block its association with steroid receptors, enhancing or reducing hormone signaling. Modulators could alter degradation or localization of misfolded proteins via SGTA-dependent pathways.